Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol for inclusion body myositis
ISRCTN80057573Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in inclusion body myositis (IBM) comparing Arimoclomol with Placebo (2 arms). Primary endpoint: Adverse events. Started Oct 2010; status: completed.
02
Drugs
arimoclomol
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on ISRCTN80057573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80057573.